Gilead Sciences, Inc. $GILD Shares Bought by TD Asset Management Inc

TD Asset Management Inc lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,424,991 shares of the biopharmaceutical company’s stock after buying an additional 4,315 shares during the quarter. TD Asset Management Inc owned approximately 0.28% of Gilead Sciences worth $380,174,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. GoalVest Advisory LLC raised its holdings in Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the last quarter. Corundum Trust Company INC purchased a new stake in shares of Gilead Sciences in the third quarter valued at $26,000. Putney Financial Group LLC increased its stake in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the last quarter. Howard Hughes Medical Institute purchased a new position in Gilead Sciences during the second quarter worth about $30,000. Finally, MTM Investment Management LLC lifted its position in Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 176 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on GILD shares. Oppenheimer upped their price objective on shares of Gilead Sciences from $128.00 to $165.00 and gave the company an “outperform” rating in a research note on Wednesday, February 11th. Morgan Stanley boosted their target price on shares of Gilead Sciences from $150.00 to $171.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Cantor Fitzgerald increased their price target on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Citigroup lifted their price target on shares of Gilead Sciences from $140.00 to $156.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. Finally, TD Cowen increased their target price on Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Twenty-three research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $155.44.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $147.64 on Wednesday. The business’s 50-day simple moving average is $134.64 and its 200 day simple moving average is $124.28. The company has a market cap of $183.17 billion, a P/E ratio of 21.81, a PEG ratio of 1.99 and a beta of 0.36. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.68. Gilead Sciences, Inc. has a one year low of $93.37 and a one year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. Gilead Sciences’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter last year, the company earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a dividend of $0.82 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. Gilead Sciences’s payout ratio is currently 46.68%.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total value of $4,324,320.00. Following the sale, the insider owned 120,288 shares in the company, valued at approximately $18,577,278.72. This represents a 18.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the transaction, the chief executive officer owned 566,698 shares of the company’s stock, valued at $76,504,230. This trade represents a 16.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 317,085 shares of company stock valued at $44,734,886 in the last 90 days. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.